BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...by Allergan Inc. Allen, who worked with Hatfield at Zafgen Inc., was VP of finance at Alnylam Pharmaceuticals Inc....
BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

...general manager for several European countries at Alnylam Pharmaceuticals Inc....
BioCentury | Jan 9, 2021
Deals

Jan. 8 Quick Takes: Alnylam’s vutrisiran headed for NDA after Phase III readout; plus AbbVie, DermBiont and FDA guidance

...By BioCentury Staff Alnylam’s vutrisiran meets Phase III amyloidosis endpointAlnylam Pharmaceuticals Inc. (NASDAQ:ALNY) will submit an...
...patients. Comments are due April 6.TARGETSIL-23 – Interleukin-23TTR – Transthyretin BC Staff vutrisiran (ALN-TTRsc02) Skyrizi, risankizumab (ABBV-066, BI 655066) Alnylam Pharmaceuticals Inc. AbbVie U.S...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

...meetings. FDA approved siRNA therapy Oxlumo lumasiran from Alnylam Pharmaceuticals Inc....
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...down from his role as EVP, CMC and continue as an executive adviser to the CEO.Alnylam Pharmaceuticals Inc....
BioCentury | Dec 16, 2020
Management Tracks

Sage puts pieces in place for growth as Greene, an architect of Alnylam, becomes CEO

...By Jeff Cranmer, Executive Editor Alnylam and Millennium...
...John Maraganore for 17 years to build Alnylam Pharmaceuticals Inc....
...president four years later.  Maraganore and Greene established Alnylam’s...
BioCentury | Dec 12, 2020
Regulation

RNA therapies get another 2020 win with inclisiran approval

...month’s FDA approval of Oxlumo lumasiran from Alnylam Pharmaceuticals Inc....
BioCentury | Dec 4, 2020
Product Development

Continuing the conversation with Henri: Termeer Square dedicated

...in the life sciences.” Maraganore is CEO of Alnylam Pharmaceuticals Inc....
...by life sciences companies and their leaders. Steve Usdin Genzyme Sanofi Alnylam Pharmaceuticals Inc. Henri...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

...unstable angina requiring hospitalization in adults with established cardiovascular disease.Leqvio inclisiran, an siRNA against PCSK9 from Alnylam Pharmaceuticals Inc....
BioCentury | Nov 25, 2020
Regulation

With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

...approval of Oxlumo to treat primary hyperoxaluria, Alnylam...
...many years for an RNAi therapy from Alnylam Pharmaceuticals Inc....
...for payers that arise with the new therapy. Alnylam...
Items per page:
1 - 10 of 993
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...by Allergan Inc. Allen, who worked with Hatfield at Zafgen Inc., was VP of finance at Alnylam Pharmaceuticals Inc....
BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

...general manager for several European countries at Alnylam Pharmaceuticals Inc....
BioCentury | Jan 9, 2021
Deals

Jan. 8 Quick Takes: Alnylam’s vutrisiran headed for NDA after Phase III readout; plus AbbVie, DermBiont and FDA guidance

...By BioCentury Staff Alnylam’s vutrisiran meets Phase III amyloidosis endpointAlnylam Pharmaceuticals Inc. (NASDAQ:ALNY) will submit an...
...patients. Comments are due April 6.TARGETSIL-23 – Interleukin-23TTR – Transthyretin BC Staff vutrisiran (ALN-TTRsc02) Skyrizi, risankizumab (ABBV-066, BI 655066) Alnylam Pharmaceuticals Inc. AbbVie U.S...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

...meetings. FDA approved siRNA therapy Oxlumo lumasiran from Alnylam Pharmaceuticals Inc....
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...down from his role as EVP, CMC and continue as an executive adviser to the CEO.Alnylam Pharmaceuticals Inc....
BioCentury | Dec 16, 2020
Management Tracks

Sage puts pieces in place for growth as Greene, an architect of Alnylam, becomes CEO

...By Jeff Cranmer, Executive Editor Alnylam and Millennium...
...John Maraganore for 17 years to build Alnylam Pharmaceuticals Inc....
...president four years later.  Maraganore and Greene established Alnylam’s...
BioCentury | Dec 12, 2020
Regulation

RNA therapies get another 2020 win with inclisiran approval

...month’s FDA approval of Oxlumo lumasiran from Alnylam Pharmaceuticals Inc....
BioCentury | Dec 4, 2020
Product Development

Continuing the conversation with Henri: Termeer Square dedicated

...in the life sciences.” Maraganore is CEO of Alnylam Pharmaceuticals Inc....
...by life sciences companies and their leaders. Steve Usdin Genzyme Sanofi Alnylam Pharmaceuticals Inc. Henri...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

...unstable angina requiring hospitalization in adults with established cardiovascular disease.Leqvio inclisiran, an siRNA against PCSK9 from Alnylam Pharmaceuticals Inc....
BioCentury | Nov 25, 2020
Regulation

With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

...approval of Oxlumo to treat primary hyperoxaluria, Alnylam...
...many years for an RNAi therapy from Alnylam Pharmaceuticals Inc....
...for payers that arise with the new therapy. Alnylam...
Items per page:
1 - 10 of 993